Background: The Ross procedure is commonly used to treat aortic valve disease in pediatric and adult patients. For infants, data are limited regarding survival, reintervention, autograft growth, and function.
Methods And Results: The Ross procedure was performed in 27 infants <18 months of age (median age 5.7 months). All patients had congenital aortic stenosis (AS); associated lesions included subAS (n=9), supravalvular AS (n=2), coarctation (n=5), and interrupted aortic arch (n=2). Median follow-up was 6.1 years (range 0.2 to 12.9). There were 3 early deaths and no late deaths. Freedom from reintervention for homograft dysfunction was 87% at 8 years; freedom from autograft reintervention was 100%. Follow-up echocardiograms were available in 17 patients. Estimated peak autograft gradient was 55 mm Hg in one patient and <10 mm Hg in 16. Mild autograft insufficiency was seen in 4 patients; 13 had none. Autograft diameter was measured early postoperatively and at latest follow-up. The mean z score increased from 0.63 to 3.2 (P<0.01) at the annulus and from 0.26 to 2.2 (P<0.01) at the sinus. In a subgroup, the mean autograft z score increased significantly from the postoperative period to 1 year for both the annulus (0.72 to 3.2, P<0.01) and the sinus (0.26 to 2.2, P<0.01), but remained unchanged thereafter.
Conclusions: The Ross procedure effectively relieves AS in infants. Homograft reintervention occurred in 13% within 8 years. No patient developed significant autograft insufficiency or required autograft reintervention during the follow-up period. Dilatation of the autograft occurred during the first year after surgery and stabilized thereafter.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1161/CIRCULATIONAHA.104.524975 | DOI Listing |
Alzheimers Dement
December 2024
LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Toronto, ON, Canada.
Background: The endocannabinoid system has demonstrated roles in Alzheimer's Disease (AD), such as modulation of inflammation. Fatty Acid Amide Hydrolase (FAAH) is the enzyme responsible for the rapid inactivation of the endocannabinoid anandamide into arachidonic acid and ethanolamine. In doing so, FAAH modulates the concentration of anandamide and influences neurobehavioral functions and physiological conditions such as nociception and inflammatory responses.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
University of North Texas Health Science Center, Fort Worth, TX, USA.
Background: Mild cognitive function (MCI) is associated with a declined short-term memory (STM). This study compared STM between adults with MCI and normal cognition assessed by verbal memory vs visuospatial memory.
Methods: Sixteen subjects with MCI and 11 subjects with normal cognition gave their written consent to participate in the study which was approved by the North Texas Regional IRB.
Front Digit Health
December 2024
Department of Health Technologies, TalTech, Tallinn, Estonia.
Introduction: Ecosystem-centered healthcare innovations, such as digital health platforms, patient-centric records, and mobile health applications, depend on the semantic interoperability of health data. This ensures efficient, patient-focused healthcare delivery in a mobile world where citizens frequently travel for work and leisure. Beyond healthcare delivery, semantic interoperability is crucial for secondary health data use.
View Article and Find Full Text PDFPhys Chem Chem Phys
January 2025
Department of Chemistry, University of Missouri, Columbia, MO 65211, USA.
We present state-to-state differential cross sections for rotationally inelastic collisions of vibrationally excited NO XΠ ( = 9) with Ar using a near-counterpropagating molecular beam geometry. These were obtained using the stimulated emission pumping technique coupled with velocity map imaging. Collision energies well over ∼1 eV were achieved and rotational excitations up to ∼Δ = 60 recorded for the first time for inelastic collisions.
View Article and Find Full Text PDFAm J Psychiatry
January 2025
Department of Psychiatry, NYU Langone Center for Psychedelic Medicine, NYU Grossman School of Medicine, New York (Pagni, Zeifman, Mennenga, Carrithers, Goldway, O'Donnell, Ross, Bogenschutz); School of Life Sciences, Arizona State University, Tempe (Mennenga); Department of Psychology, New York University, New York (Goldway); Department of Psychiatry and Behavioral Sciences, University of New Mexico School of Medicine, Albuquerque (Bhatt).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!